Characteristics of a novel NMR-based metabolomics platform for dogs

Claudia Ottka^{1*}, Katariina Vapalahti^{1,2,3}, Jenni Puurunen^{2,3}, Laura Vahtera^{2,3}, Hannes Lohi^{1,2,3*}.

¹ PetBIOMICS Ltd, Helsinki, Finland

² Department of Veterinary Biosciences and Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland

³ Folkhälsan Research Center, Helsinki, Finland

Claudia Ottka

claudia.ottka@petbiomics.com

<https://orcid.org/0000-0003-4837-6309>

Katariina Vapalahti

<https://orcid.org/0000-0002-0855-8776>

Jenni Puurunen

<https://orcid.org/0000-0001-5166-493X>

Laura Vahtera

<https://orcid.org/0000-0002-5198-9870>

Hannes Lohi

hannes.lohi@helsinki.fi

<https://orcid.org/0000-0003-1087-5532>

*corresponding authors

Abstract

Metabolomics has proven itself an invaluable research tool, providing comprehensive insight to systemic metabolism. However, the lack of scalable and quantitative methods with known reference intervals and documented reproducibility has prevented the use of metabolomics in the clinical setting. This study describes the development and validation of a quantitative nuclear magnetic resonance (NMR) -based metabolomics platform for canine serum and plasma samples. Altogether 8247 canine samples were analyzed using a Bruker's 500 MHz NMR spectrometer. Using statistical approaches derived from international guidelines, we defined reference intervals for 123 biomarkers, studied method precision, analyte storage stability, the effect of prolonged contact to red blood cells, differences of blood collection

tubes, interference of lipemia, hemolysis and bilirubinemia, method comparison, and demonstrated the method's practical relevance in a hyperglycemic cohort. Owing to the advantages of quantitative results, high reproducibility, and scalability, this canine metabolomics platform holds great potential for numerous clinical and research applications to improve canine health and well-being.

Keywords: canine, metabolomics, NMR, reference intervals, precision, stability

Metabolomics is an omics-based approach that generates comprehensive information on metabolism, enabling an extensive view on the current state of systemic metabolism. Metabolomics has become increasingly popular in canine studies. It is especially suitable in characterizing metabolic effects of multiple environmental and inter- and intra-individual factors including feeding²⁻⁶, aging⁷, inter-breed differences^{8,9}, drug action^{10,11}, behavior^{12,13}, exercise¹⁴, genetic factors¹⁵ and pathological processes¹⁶⁻²⁶.

Mass spectrometry (MS) and proton nuclear magnetic resonance (NMR) spectroscopy are the two main technologies for metabolic profiling, both in human and animal studies²⁷. Proton NMR spectroscopy offers quantitative data with high reproducibility, high throughput and excellent scalability in a non-destructive and cost-effective manner²⁷. NMR spectroscopy is well suited for the scientific use of large cohorts and biobanks^{28,29} and is highly suitable for studies combining different omics technologies²⁹⁻³¹. Due to the quantitative and highly reproducible nature of NMR spectroscopy, it can be easily utilized as a diagnostic tool and research findings can be easily applied to clinical use.

Metabolomics holds great potential in clinical diagnostics. It is a promising tool for highlighting the metabolic alterations associated with the emergence and progression of diseases, early disease detection and individualization of treatment³²⁻³⁴. Clinical diagnostics and decision-making have formerly relied on the use of single clinical chemistry biomarkers. The routinely used approach is largely unusable for risk prediction, since changes are typically only seen when the diseased state has already been reached^{33,35}. Thus, preventive and supportive care measures cannot be undertaken before organ failure is already present. Interpretation of the results by the traditional approach might also be challenging, since multiple simultaneous metabolic phenomena can affect the interpretation of these results and multiple diseases can be associated with similar laboratory results^{22,35-37}. Moreover, evaluations of disease severity lack accuracy when only one affected metabolic pathway is taken into account^{34,37}. Furthermore, traditional diagnostic approaches do not take the metabolic state of the patient into account, although it might have an impact on the best treatment of the patient^{34,38}.

The prerequisites for the utility of a particular method include documentation of the method's reproducibility, understanding of confounding factors that might affect the interpretation of the results, and the formation of reference intervals³⁹. All of these factors have previously been largely unpublished in the canine metabolomics field. In this study, we describe the development and validation of a novel NMR-based metabolomics platform for dogs, demonstrate its performance characteristics, publish the determined dog-specific reference intervals for its biomarkers and demonstrate its utility in a practical situation.

Results

To develop and validate a quantitative NMR-based approach for canine metabolomics, a total of 8247 serum or plasma samples were collected and analyzed. Thirty of these were pooled samples, 912 were replicate samples of client-owned dogs, 999 leftover clinical laboratory samples, and 6306 were single samples of client-owned dogs (Supplementary Figure 1). The number of individual client-owned dogs with samples collected during this project was 6164 (Supplementary Table 1). Eighteen percent of the dogs were under one year of age, 61% aged 1-7, and 21% over 7 years of age. Males consisted 40% of the population and samples were taken from 256 breeds.

Proton NMR spectroscopy quantitates 123 biomarkers

All samples were analyzed with Bruker's 500 MHz NMR spectrometer with spectral data interpreted by in-house scripts following principles demonstrated for human samples⁴⁰. The NMR method was able to quantify 123 biomarkers, including extensive lipoprotein profiling, fatty acids, amino acids, albumin, creatinine and glycolysis related metabolites, in canine serum/plasma (Fig 1).

BIOMARKERS

<i>Creatinine mmol/l</i>	<i>Cholesterol mmol/l</i>	<i>Lipoprotein subclass particle concentration and composition mmol/l</i>
<i>Albumin g/l</i>	Cholesterol VLDL cholesterol LDL cholesterol HDL cholesterol Free cholesterol Esterified cholesterol	XL-VLDL particles L-VLDL particles S-VLDL particles L-LDL particles S-LDL particles XL-HDL particles L-HDL particles S-HDL particles XL-VLDL lipids L-VLDL lipids S-VLDL lipids L-LDL lipids S-LDL lipids XL-HDL lipids L-HDL lipids S-HDL lipids XL-VLDL cholesterol L-VLDL cholesterol S-VLDL cholesterol L-LDL cholesterol S-LDL cholesterol XL-HDL cholesterol L-HDL cholesterol S-HDL cholesterol XL-VLDL esterified cholesterol L-VLDL esterified cholesterol S-VLDL esterified cholesterol L-LDL esterified cholesterol S-LDL esterified cholesterol XL-HDL esterified cholesterol L-HDL esterified cholesterol S-HDL esterified cholesterol XL-VLDL free cholesterol L-VLDL free cholesterol S-VLDL free cholesterol L-LDL free cholesterol S-LDL free cholesterol XL-HDL free cholesterol L-HDL free cholesterol S-HDL free cholesterol XL-VLDL triglycerides L-VLDL triglycerides S-VLDL triglycerides L-LDL triglycerides S-LDL triglycerides XL-HDL triglycerides L-HDL triglycerides S-HDL triglycerides XL-VLDL phospholipids L-VLDL phospholipids S-VLDL phospholipids L-LDL phospholipids S-LDL phospholipids XL-HDL phospholipids L-HDL phospholipids S-HDL phospholipids
<i>Glycolysis related metabolites mmol/l</i>	<i>Lipoprotein particles mmol/l</i>	
Glucose Lactate Pyruvate* Citrate Acetate	VLDL particles LDL particles HDL particles VLDL lipids LDL lipids HDL lipids	
<i>Triglycerides mmol/l</i>	<i>nm</i>	
Triglycerides VLDL triglycerides LDL triglycerides HDL triglycerides	VLDL particle size LDL particle size HDL particle size	
<i>Inflammation mmol/l</i>	<i>Fatty acids mmol/l</i>	
Glycoprotein acetyls	Palmitic acid Stearic acid Oleic acid Linoleic acid Arachidonic acid Docosapentaenoic acid Docosahexaenoic acid Omega-3 fatty acids Omega-6 fatty acids Polyunsaturated fatty acids Saturated fatty acids Total fatty acids	
<i>Amino acids mmol/l</i>	<i>% of total fatty acids</i>	
Alanine Glutamine Glycine* Histidine Isoleucine Leucine Valine Phenylalanine Tyrosine BCAA	Palmitic acid% Stearic acid% Oleic acid% Linoleic acid% Arachidonic acid% Docosapentaenoic acid% Docosahexaenoic acid% Omega-3 fatty acids% Omega-6 fatty acids% Polyunsaturated fatty acids% Saturated fatty acids%	
<i>Ratio</i>	<i>Ratio</i>	
Glycine/BCAA BCAA/Tyrosine Phenylalanine/tyrosine Glycine/valine Alanine/BCAA Alanine/valine	Omega-6/omega-3 fatty acids	

Fig 1. The biomarkers quantified by the NMR metabolomics testing platform.

*: not available from EDTA-plasma samples.

BCAA: Branched-chain amino acids

XL-VLDL: Chylomicrons and very large VLDL-particles

L-VLDL: large VLDL particles

S-VLDL: small VLDL-particles

L-LDL: large LDL particles

S-LDL: small LDL particles

XL-HDL: very large HDL particles

L-HDL: large HDL particles

S-HDL: small HDL particles

Reference intervals for puppies, adult and senior dogs

We determined reference intervals (RI) (Table 1, Supplementary Table 2) with 90% confidence intervals (CI)

(Supplementary Table 2) for 123 metabolites in serum and heparin plasma samples.

In certain analytes, such as XL-VLDL variables, the concentration in healthy animals was very low, causing highly skewed distributions. Also, automatic rejection of extremely low values by the platform's quality control, caused inability to calculate CIs with the used non-parametric method. For these analytes, the lower reference limit was rounded to 0. For a multitude of analytes, the 90% CI width was higher than 20% of the RI width, due to skewed or heavy tailed distributions. This was especially observed in RI for puppies and senior dogs, where the n count was lower (n < 170) than in adult dogs. However, for some analytes, it was also observed in RIs with very high n counts (n > 800).

RIs of puppies differed from the RIs of adult dogs in many analytes, such as glucose, lactate, creatinine, albumin, glycine, glutamine, leucine, valine, branched chain amino acids (BCAA), VLDL particle size, and HDL and LDL triglycerides. The higher reference limit (RL) of senior dogs exceeded the higher RL of adult dogs for alanine, tyrosine, alanine/BCAA, glycoprotein acetyls (GlycA), oleic acid, docosahexaenoic acid%, HDL triglycerides, S-VLDL lipids and L-HDL triglycerides.

Table 1. Established reference intervals for the validated biomarkers.

Analyte	HP all dogs	S all dogs	S puppy	S adult	S senior
Glucose mmol/l	4.3-6.8	4.4-6.8	4.7-7.3 ^a	4.4-6.6	4.0-6.1
Lactate mmol/l	0.7-3.0	1.1-3.6	1.3-2.9 ^b	1.1-3.6	1.1-4.2
Creatinine mmol/l	40-99	32-103	21-96 ^b	40-108	37-104
Albumin mg/dl	26-32	25-32	22-31 ^b	26-32	26-32
Cholesterol mmol/l	3.8-10.4	3.6-10.3	3.8-10.1	3.6-10.3	3.5-10.6
Triglycerides mmol/l	0.22-0.97	0.19-1.00	0.18-0.76	0.19-0.97	0.19-1.13
Pyruvate μmol/l	29-155	11-107	9-96	11-111	13-109
Citrate μmol/l	63-122	61-123	57-115	61-124	62-128
Acetate μmol/l	19-36	21-37	22-40	21-37	20-37
Alanine μmol/l	214-584	216-597	205-504	205-583	244-650 ^a
Glycine μmol/l	147-466	130-454	145-594 ^{a,b}	127-381	128-403
Glutamine μmol/l	570-919	640-1,015	642-997 ^b	659-1,028	616-1,014
Histidine μmol/l	50-91	53-98	46-93	55-99	55-97

Isoleucine $\mu\text{mol/l}$	33-80	37-89	30-80 ^a	38-92	38-87
Leucine $\mu\text{mol/l}$	74-168	83-185	67-159 ^b	89-186	94-186
Valine $\mu\text{mol/l}$	107-245	113-251	80-236 ^b	119-260	124-253
Phenylalanine $\mu\text{mol/l}$	32-64	30-65	28-66	29-64	34-66
Tyrosine $\mu\text{mol/l}$	39-85	41-89	39-83	41-90	46-93 ^a
BCAA $\mu\text{mol/l}$	222-482	242-515	178-462 ^b	261-524	251-521
Glycine/BCAA	0.3-1.4	0.3-1.5	0.4-3.0 ^a	0.3-1.2	0.3-1.2
BCAA/Tyrosine	3.7-9.5	3.8-9.2	3.8-8.3 ^a	3.9-9.5	3.5-8.6
Phenylalanine/tyrosine	0.6-1.2	0.5-1.0	0.5-1.1	0.5-1.0	0.5-1.0
Glycine/valine	0.6-2.6	0.7-3.0	0.9-6.8 ^a	0.7-2.5	0.7-2.6
Alanine/BCAA	0.7-2.0	0.6-1.6	0.6-1.4	0.5-1.6	0.6-1.8 ^a
Alanine/valine	1.3-3.7	1.2-3.5	1.3-3.0	1.1-3.5	1.3-3.8
VLDL lipids mmol/l	0.1-1.1	0.1-1.2	0.1-0.8	0.1-1.1	0.1-1.3
VLDL particles nmol/l	15-54	12-54	14-45	12-51	12-67
LDL lipids mmol/l	0.5-3.7	0.7-3.7	0.7-3.7	0.7-3.6	0.7-4.5
LDL particles nmol/l	200-1,400	240-1,300	270-1,300	240-1,300	240-1,600
HDL lipids mmol/l	7.7-14.6	6.9-15.1	7.2-15.0	6.9-15.1	6.6-15.3
HDL particles nmol/l	32,000-57,000	30,000-58,000	33,000-58,000	30,000-59,000	28,000-58,000
VLDL particle size nm	35.8-43.6	35.2-43.8	35.1-41.7 ^a	35.3-43.8	35.4-44.4
LDL particle size nm	22.1-23.9	22.2-23.5	22.3-23.5	22.2-23.4	22.2-23.5
HDL particle size nm	10.1-10.7	10.1-10.7	10.1-10.6	10.0-10.6	10.1-10.7
VLDL cholesterol mmol/l	0.03-0.31	0.03-0.31	0.03-0.23	0.03-0.29	0.03-0.36
LDL cholesterol mmol/l	0.16-2.35	0.28-2.27	0.30-2.24	0.28-2.21	0.28-2.85
HDL cholesterol mmol/l	3.6-8.0	3.2-7.9	3.6-7.9	3.2-7.9	3.0-8.0
Esterified cholesterol mmol/l	3.1-8.2	2.9-8.1	3.2-8.0	2.9-8.1	2.9-8.4
Free cholesterol mmol/l	0.7-2.2	0.6-2.2	0.7-2.0	0.6-2.2	0.6-2.4
VLDL triglycerides mmol/l	0.02-0.70	0.00-0.70	0.00-0.44	0.00-0.69	0.00-0.86
LDL triglycerides mmol/l	0.13-0.30	0.13-0.31	0.15-0.33 ^a	0.13-0.29	0.14-0.27
HDL triglycerides mmol/l	0.01-0.08	0.00-0.08	0.00-0.04 ^b	0.00-0.07	0.01-0.09 ^a
Glycoprotein acetyls $\mu\text{mol/l}$	532-964	597-1,028	611-996	596-1,005	605-1,129 ^a
Palmitic acid mmol/l	1.9-3.5	1.8-3.6	1.8-3.4	1.8-3.6	1.8-3.9
Stearic acid mmol/l	1.9-3.8	1.7-3.8	1.8-3.7	1.7-3.9	1.7-4.0

Oleic acid mmol/l	1.1-2.5	1.3-2.8	1.3-2.5	1.3-2.8	1.3-3.2 ^a
Linoleic acid mmol/l	2.7-5.7	2.5-5.9	2.5-5.1	2.5-5.9	2.5-6.2
Arachidonic acid mmol/l	1.6-3.7	1.4-3.6	1.5-3.7	1.4-3.6	1.3-3.7
Docosapentaenoic acid mmol/l	0.1-0.3	0.1-0.4	0.1-0.3	0.1-0.4	0.1-0.4
Docosahexaenoic acid mmol/l	0.1-0.9	0.1-0.7	0.1-0.8	0.1-0.7	0.1-0.8
Omega-3 fatty acids mmol/l	0.4-1.8	0.4-1.6	0.4-1.6	0.4-1.6	0.5-1.8
Omega-6 fatty acids mmol/l	4.5-9.6	4.1-9.8	4.2-9.3	4.1-9.6	3.9-10.6
Polyunsaturated fatty acids mmol/l	5.2-10.8	4.7-11.1	4.8-10.6	4.7-11.0	4.6-12.0
Saturated fatty acids mmol/l	3.9-7.2	3.6-7.4	3.6-6.8	3.6-7.5	3.5-7.7
Total fatty acids mmol/l	10.5-20.4	9.7-21.0	9.8-20.0	9.7-21.2	9.3-22.5
Palmitic acid%	15.9-19.8	16-20	16-19	16-19	16-20
Stearic acid%	17.5-19.5	17.3-19.4	17.5-19.3	17.4-19.5	17.1-19.4
Oleic acid%	9.2-14.2	10.7-15.1	10.6-14.2 ^a	10.9-15.1	10.9-15.7
Linoleic acid%	23.9-29.4	24.1-28.6	23.3-27.5 ^{a,b}	24.5-28.6	24.7-28.7
Arachidonic acid%	13.6-20.7	13.2-20.1	15.0-20.7 ^{a,b}	13.1-19.9	12.7-19.2
Docosapentaenoic acid%	0.9-1.9	1.1-2.0	1.1-1.9	1.1-1.9	1.1-2.0
Docosahexaenoic acid%	0.9-6.2	0.7-4.8b	1.0-5.2 ^b	0.7-4.7	0.6-5.0 ^a
Omega-3 fatty acids%	3-12	3-10	3-11	3-11	4-11
Omega-6 fatty acids%	43-49	42-48	42-48	42-48	42-47
Polyunsaturated fatty acids%	48-57	48-55	48-55 ^b	47-55	47-55
Saturated fatty acids%	34-39	34-38	34-38	34-38	33-38
Omega-6/omega-3 fatty acids	3.5-16.3	4.2-13.4	4.1-13.5	4.2-14.2	4.0-13.1
XL-VLDL particles nmol/l	0-2	0-1	0-1	0-1	0-2
L-VLDL particles nmol/l	1-15	0-16	0-11 ^a	0-15	0-19
S-VLDL particles nmol/l	11-38	10-39	13-34	10-37	10-47
L-LDL particles nmol/l	79-380	90-370	110-350	91-380	83-400
S-LDL particles nmol/l	89-1000	140-960	130-940	130-920	140-1,100
XL-HDL particles nmol/l	1-6,200	0-5,800	25-5,500	0-5,800	1-6,000
L-HDL particles nmol/l	21,000-34,000	20,000-34,000	20,000-34,000	19,000-35,000	18,000-34,000
S-HDL particles nmol/l	11,000-19,000	11,000-20,000	11,000-19,000	11,000-20,000	10,000-20,000

XL-VLDL lipids mmol/l	0-0.3	0-0.3	0-0.2	0-0.2	0-0.4
L-VLDL lipids mmol/l	0-0.6	0-0.6	0-0.4 ^a	0-0.6	0-0.7
S-VLDL lipids mmol/l	0.1-0.4	0.1-0.4	0.1-0.3	0.1-0.3	0.1-0.4 ^a
L-LDL lipids mmol/l	0.2-1.2	0.3-1.2	0.3-1.1	0.3-1.2	0.3-1.3
S-LDL lipids mmol/l	0.2-2.6	0.3-2.4	0.3-2.4	0.3-2.3	0.3-2.9
XL-HDL lipids mmol/l	0.6-5.2	0.6-5.0	0.6-4.7	0.6-5.0	0.7-5.2
L-HDL lipids mmol/l	5.4-8.1	5.0-8.3	5.0-8.1	4.9-8.3	4.8-8.3
S-HDL lipids mmol/l	1.3-2.1	1.3-2.2	1.3-2.1	1.3-2.2	1.1-2.2
XL-VLDL cholesterol mmol/l	0-0.06	0-0.06	0-0.04	0-0.06	0-0.08
L-VLDL cholesterol mmol/l	0-0.13	0-0.13	0-0.08	0-0.12	0-0.15
S-VLDL cholesterol mmol/l	0.01-0.14	0.02-0.15	0.02-0.11	0.02-0.14	0.02-0.18
L-LDL cholesterol mmol/l	0.03-0.70	0.07-0.68	0.11-0.61	0.07-0.68	0.07-0.76
S-LDL cholesterol mmol/l	0.09-1.64	0.16-1.53	0.16-1.50	0.16-1.48	0.18-1.88
XL-HDL cholesterol mmol/l	0.3-3.0	0.2-2.8	0.3-2.9	0.2-2.7	0.2-2.9
L-HDL cholesterol mmol/l	2.6-4.3	2.3-4.4	2.5-4.3	2.3-4.5	2.2-4.4
S-HDL cholesterol mmol/l	0.5-1.0	0.5-1.0	0.6-1.0	0.5-1.0	0.5-1.0
XL-VLDL esterified cholesterol mmol/l	0-0.03	0-0.03	0-0.02	0-0.03	0-0.03
L-VLDL esterified cholesterol mmol/l	0-0.05	0-0.06	0-0.04	0-0.05	0-0.07
S-VLDL esterified cholesterol mmol/l	0-0.09	0.01-0.09	0.01-0.08	0.01-0.09	0.01-0.11
L-LDL esterified cholesterol mmol/l	0.01-0.51	0.03-0.49	0.05-0.43	0.02-0.48	0.02-0.55
S-LDL esterified cholesterol mmol/l	0.05-1.14	0.10-1.09	0.10-1.06	0.10-1.06	0.12-1.35
XL-HDL esterified cholesterol mmol/l	0.2-2.3	0.2-2.1	0.2-2.1	0.2-2.1	0.2-2.3
L-HDL esterified cholesterol mmol/l	2.3-3.7	2.0-3.8	2.2-3.7	2.0-3.8	1.9-3.8
S-HDL esterified cholesterol mmol/l	0.4-0.8	0.4-0.8	0.5-0.8	0.4-0.8	0.4-0.8
XL-VLDL free cholesterol mmol/l	0-0.05	0-0.05	0-0.03	0-0.04	0-0.05
L-VLDL free cholesterol mmol/l	0-0.08	0-0.08	0-0.05 ^a	0-0.07	0-0.10
S-VLDL free cholesterol mmol/l	0.01-0.05	0.01-0.06	0.01-0.05	0.01-0.05	0.01-0.07
L-LDL free cholesterol mmol/l	0.03-0.20	0.04-0.20	0.05-0.18	0.04-0.20	0.04-0.21
S-LDL free cholesterol mmol/l	0.04-0.48	0.05-0.45	0.06-0.45	0.05-0.43	0.05-0.53
XL-HDL free cholesterol mmol/l	0.1-0.7	0.1-0.6	0.1-0.6	0.1-0.6	0.1-0.6
L-HDL free cholesterol mmol/l	0.3-0.6	0.3-0.6	0.3-0.6	0.3-0.6	0.3-0.6
S-HDL free cholesterol mmol/l	0.1-0.2	0.1-0.2	0.1-0.2	0.1-0.2	0.1-0.2

XL-VLDL triglycerides mmol/l	0-0.22	0-0.17	0-0.13	0-0.17	0-0.24
L-VLDL triglycerides mmol/l	0.01-0.41	0.01-0.42	0.00-0.27 ^b	0.01-0.39	0.01-0.49
S-VLDL triglycerides mmol/l	0.03-0.16	0.02-0.16	0.02-0.13	0.01-0.15	0.02-0.19
L-LDL triglycerides mmol/l	0.11-0.24	0.10-0.24	0.11-0.26 ^{a,b}	0.09-0.23	0.10-0.22
S-LDL triglycerides mmol/l	0.02-0.07	0.03-0.07	0.03-0.08	0.03-0.07	0.03-0.07
XL-HDL triglycerides mmol/l	0-0.02	0-0.02	0-0.02	0-0.02	0-0.03
L-HDL triglycerides mmol/l	0.01-0.03	0-0.03	0-0.02	0-0.03	0-0.04 ^a
S-HDL triglycerides mmol/l	0-0.04	0-0.03	0-0.02	0-0.03	0-0.04
XL-VLDL phospholipids mmol/l	0-0.05	0-0.05	0-0.04	0-0.05	0-0.09
L-VLDL phospholipids mmol/l	0-0.09	0-0.11	0-0.06	0-0.10	0-0.15
S-VLDL phospholipids mmol/l	0.01-0.07	0.01-0.08	0.01-0.06	0-0.08	0.01-0.10
L-LDL phospholipids mmol/l	0.08-0.33	0.08-0.32	0.09-0.33	0.07-0.30	0.08-0.35
S-LDL phospholipids mmol/l	0.08-0.87	0.12-0.84	0.12-0.80	0.12-0.80	0.12-1.01
XL-HDL phospholipids mmol/l	0.35-2.27	0.33-2.22	0.32-1.97	0.30-2.21	0.34-2.37
L-HDL phospholipids mmol/l	2.65-3.92	2.48-3.94	2.61-3.79	2.44-3.95	2.56-4.01
S-HDL phospholipids mmol/l	0.74-1.18	0.72-1.19	0.76-1.14 ^a	0.72-1.19	0.67-1.21

107 HP all dogs n = 269, S all dogs n = 865, S puppy n = 152, S adult n = 545, S senior n = 168.

108 HP: heparinized plasma

109 S: serum

110 BCAA: Branched-chain amino acids

111 ^a: no overlap between the 90% CI of the upper reference limit of this age group compared to adult dogs

112 ^b: no overlap between the 90% CI of the lower reference limit of this age group compared to adult dogs

113

114 Precision of the platform

115 We studied analysis precision using three biologically different dogs, with duplicate aliquots of each dog's sample

116 analyzed once a day during a twenty-day period (Supplementary Table 3). The aliquots from a senior dog suffering

117 from hyperadrenocorticism showed marked chylomicronemia, and was excluded from method precision estimations.

118 Outlier removal slightly affected result interpretation, thus results were evaluated with outliers removed. In the

119 primarily evaluated (non-chylomicronemic) samples, 110/123 biomarkers reached all of their precision goals. Albumin

120 did not reach its primary precision goal of ASVCP CV_{min} based on biological variation, but reached all its other

121 precision goals; CV% goal based on ASVCP Clinical Decision Limits and the S_T goal of under 1/8 reference width

(S_{Tmax}). Histidine, acetate, phenylalanine/tyrosine and BCAA/tyrosine met their primary precision goal of CV% under 20% (CV_{maxBG}), but did not meet their secondary precision goal of S_{Tmax} . 12/123 biomarkers did not reach their primary precision goal of CV_{maxBG} , but reached the S_{Tmax} goal. All of these analytes were lipid analytes with high inter-individual biological variation and large reference interval width, and were in low concentrations in the tested samples. The CV_{maxBG} goal was thus regarded inappropriate for these analytes, since the variation in these analytes' concentrations was not considered to affect clinical decision-making.

Chylomicronemia caused imprecision in multiple lipid measurements as well as in creatinine and the amino acids leucine and phenylalanine. Precision of glutamine was non-evaluable, since the olefin oligomer gel in the sample tubes inhibited correct glutamine estimation from the NMR signal. The precision of XL-VLDL phospholipids was non-evaluable due to a large amount of missing observations caused by physiologically very low analyte concentrations in healthy dogs.

The effect of sample storage on biomarker stability

All evaluated analytes remained stable in refrigerated temperature for 7 days (Table 2, Supplementary Table 4). Most of the analytes remained also stable at room temperature for 7 days. Unstable metabolites in room temperature were the amino acids histidine, isoleucine, glutamine, tyrosine and phenylalanine, acetate, triglycerides and certain lipoprotein particle constituent concentrations as well as the fatty acid docosapentaenoic acid. The stability of all other amino acids than glutamine was better in EDTA-plasma than in serum. Glutamine concentration changed significantly at 4 days of storage at room temperature in EDTA-plasma samples and at 7 days of storage in serum samples. The acceptable change limit (ACL) of glutamine and XL-VLDL phospholipids could not be calculated using the analysis mean coefficient of variation (CVa), since these were not available from the precision study. The changes observed in triglyceride concentrations at room temperature originate from the computational quantitation based on lipoprotein particle distribution and the lipid quantity in the lipoprotein particle core and their outer surface. These are slightly affected by sample storage at room temperature, thus affecting triglyceride quantitation.

All of the evaluated analytes were stable at -80°C for 12 months. Storage at -20°C affected certain lipoprotein particles and their composition, certain fatty acids, citrate, acetate and GlycA. Citrate levels were significantly ($p < 0.05$) changed already at one week of storage at -20°C.

Heparin plasma storage samples rarely made under the p-value of 0.05, even when the mean percentage deviation (MPD) exceeded the ACL and statistically significant ($p < 0.05$) changes were noted in other sample types.

150 Outlier removal slightly affected result interpretation in serum and EDTA plasma, thus their results were evaluated after
151 outlier removal. In heparin plasma, outliers could not be reliably identified due to the small sample size (n = 4).
152 Table 2. Critical storage times for analytes sensitive to certain storage conditions in at least one sample type.

Analyte	Temperature	Storage time _{Serum} (p)	Storage time _{EDTA} (p)	Storage time _{HP} (p)
Glutamine	RT	7 days^a (0.00[*])	4 days^a (0.04[*])	4 days^a (0.11)
Histidine	RT	3 days (0.00[*])	NO	3 days (0.03[*])
Isoleucine	RT	2 days (0.04[*])	NO	4 days (0.20)
Phenylalanine	RT	3 days (0.00[*])	NO	7 days (0.06)
Tyrosine	RT	3 days (0.01[*])	NO	NO
HDL triglycerides	RT	2 days (0.01[*])	4 days (0.07)	4 days (0.20)
LDL triglycerides	RT	2 days (0.01[*])	4 days (0.02[*])	2 days (0.20)
VLDL triglycerides	RT	2 days (0.00[*])	2 days (0.04[*])	4 days (0.11)
Triglycerides	RT	24 hours (0.04[*])	2 days (0.02[*])	2 days (0.20)
Acetate	RT	4 days (0.02[*])	7 days (0.00[*])	4 days (0.03[*])
Docosapentaenoic acid	RT	7 days (0.03[*])	NE	7 days (0.20)
Citrate	-20°C	1 week (0.00[*])	NO	-
Acetate	-20°C	3 months (0.00[*])^b	6 months (0.00[*])	-
Glycoprotein acetyls	-20°C	1 month (0.00[*])	1 month (0.01[*])	-
Omega-3 fatty acids	-20°C	6 months (0.02[*])	NE	-
HDL particle size	-20°C	3 months (0.04[*])	3 months (0.03[*])	-
HDL particles	-20°C	6 months (0.00[*])	6 months (0.00[*])	-
LDL lipids	-20°C	NE	6 months (0.03[*])	-
LDL particles	-20°C	NE	6 months (0.03[*])	-
LDL cholesterol	-20°C	NE	6 months (0.03[*])	-
VLDL particles	-20°C	6 months (0.04[*])	6 months (0.01[*])	-

153 The storage time presented in the table represents the time point, where statistically significant changes (two-sided
154 Wilcoxon exact test $p < 0.05$), with a mean percentage deviation (MPD) exceeding the acceptable change limit (ACL)
155 are first observed. In sample types where statistical significance was not observed ($p \geq 0.05$), the storage times represent
156 the time point, where the MPD first exceeds the ACL. This table includes only primary analytes. Lipoprotein particle
157 subclasses are not included. Stability at -20°C and -80°C were not studied in heparin plasma. $n_{\text{serum}} = 7$, $n_{\text{EDTA}} = 7$, $n_{\text{HP}} =$
158 4.

159

160 RT: room temperature

161 *: $p < 0.05$

162 NO: no change observed

163 NE: not evaluable due to discrepancies in p-values and MPD vs ACL. Results in other sample types should be consulted
164 until further studies are conducted.

165 ^a ACL unknown, evaluated only as $p < 0.05$, time in heparin plasma represents the time, where a change in similar
166 magnitude as in serum and EDTA plasma is observed

167 ^b At 6 months of storage, MPD returned below the ACL and $p > 0.05$

168 The effect of delayed plasma separation on biomarker stability

169 We studied the effect of delayed plasma separation in 34 EDTA plasma samples, which had been stored as whole blood
170 in the refrigerator for 24 and 48 hours before separating plasma (Supplementary Table 5, table 3). Outlier removal
171 slightly affected result interpretation, thus the results were evaluated after outlier removal. Prolonged contact with red
172 blood cells (RBC) affected the concentration of many of the analytes. Significant changes ($p < 0.05$, $MPD > ACL$) after
173 one day's contact to RBCs in refrigerator temperature were observed for glucose and lactate. After two days' contact
174 with RBCs, significant changes were observed for citrate, amino acids alanine, histidine, isoleucine, leucine, valine,
175 phenylalanine and tyrosine, cholesterol, triglycerides, and lipoprotein particles and their constituents. Glutamine values
176 were also changed significantly ($p < 0.05$) at 48 hours of storage as whole blood, but MPD could not be evaluated
177 against the ACL due to the missing ACL.

178 Table 3. Critical storage times as whole blood for analytes sensitive to storage as whole blood.

Analyte	Storage time (p)
Glucose	24 hours (0.00)
Lactate	24 hours (0.00)
Citrate	48 hours (0.00)
Alanine	48 hours (0.00)
Glutamine	48 hours ^a (0.00)
Histidine	48 hours (0.00)
Isoleucine	48 hours (0.00)
Leucine	48 hours (0.01)
Valine	48 hours (0.00)
Phenylalanine	48 hours (0.00)

Tyrosine	48 hours (0.00)
HDL lipids	48 hours (0.03)
HDL particles	48 hours (0.00)
LDL diameter	48 hours (0.00)
VLDL diameter	48 hours (0.04)
Cholesterol	48 hours (0.02)
HDL cholesterol	48 hours (0.00)
Esterified cholesterol	48 hours (0.00)
Triglycerides	48 hours (0.00)
VLDL triglycerides	48 hours (0.00)

The storage time presented in the table represents the time point, where statistically significant changes (two-sided Wilcoxon exact test $p < 0.05$) together with a mean percentage deviation (MPD) exceeding the acceptable change limit (ACL) are first observed. $n = 34$. This table includes only primary analytes. Lipoprotein particle subclasses are not included.

^a ACL unknown

Sample tube validation

We studied the differences of seven different sample tubes and the variability between their two sample lots using samples from 20 client-owned dogs (Supplementary Table 6). Outlier removal did not affect result interpretation, thus results were evaluated without outlier removal.

Firstly, the different sample tubes were compared to the primary reference tube (Vacuette Lithium Heparin). Most analytes showed comparable results in all tube types compared to the primary reference tube. Significant differences ($p < 0.05$) with $MPD > ACL$ were noted for citrate, glucose, lactate and GlycA and significant differences ($p < 0.05$) with $MPD < ACL$ were observed for glutamine, histidine, pyruvate and acetate. Glutamine showed significant differences ($p < 0.05$) compared to the primary reference tube, but its ACL was not available. Most of this variability was observed between analyte values in serum and plasma.

Secondly, analyte values in all serum tubes were compared to the reference serum tube (Vacuette Z Serum Clot Activator). All serum tubes showed comparable results with the serum reference tube for all metabolites.

The only lot-to-lot variability was observed in MiniCollect Serum gel tubes for glutamine and GlycA. Results obtained by both of these tube lots were still comparable to the reference serum tube (Vacuette Z Serum Clot Activator). In these

MiniCollect Serum gel tubes, the two lots represented tubes of old-type (lot A) and new-type (lot B) tubes, with the tube having undergone changes in physical appearance, while sample tube constituents had remained the same.

Interference studies

We studied the interference of hemolysis, lipemia, and unconjugated and conjugated bilirubin using triplicate samples of two different test pools for hemolysis and bilirubinemia and from one pool for lipemia (Supplementary Table 7). Hemolysis interfered with the quantitation of albumin and certain lipids; lipoprotein particle cholesterol concentrations, total triglycerides and certain lipoprotein triglyceride measures, multiple fatty acids, LDL and VLDL particle size, certain lipoprotein particle concentrations, lipoprotein phospholipids and certain lipoprotein lipids. Bilirubinemia interfered only with the quantitation of L-VLDL esterified cholesterol and S-HDL triglycerides. Lipemia affected the quantitation of GlycA due to the lipid contribution to the GlycA signal. However, the concentration of GlycA remained above the reference interval after the removal of lipids, indicating that lipemia was not the sole cause for raised GlycA concentration in the lipemic pool.

Method comparison

Using 999 clinical canine samples, we evaluated, whether results of routine clinical chemistry analytes in the NMR metabolomics platform are comparable with results obtained by conventional clinical chemistry methods (Supplementary Table 8). The tested metabolites were glucose, lactate, creatinine, albumin, cholesterol and triglycerides. The tested samples covered the clinical concentration ranges for all analytes. The comparison plots showed satisfactory agreement between the two methods for all analytes. In some metabolites, logarithm transformation showed better agreement than initial data, suggesting better agreement in the transformed data.

Glucose, lactate and albumin measurements reached the Total Allowable Error (TE_a) goals based on ASVCP Clinical Decision limits⁴¹, indicating that the two methods can be used interchangeably without affecting clinical decision-making. The bias percentage of creatinine, cholesterol and triglycerides was too high for the analytes to reach the TE_a goals based on Clinical Decision limits, meaning that the two methods cannot be used interchangeably. Values obtained by the conventional method can be evaluated against values obtained by the NMR method using the slope and intercept calculated by Deming regression.

Hyperglycemia associates with many metabolic changes

We evaluated the practical relevance of the NMR metabolomics platform by comparing the metabolic profile of a markedly hyperglycemic group ($n = 24$) to a normoglycemic group of routine laboratory diagnostic samples ($n = 781$). Several biomarkers with previously reported changes in canine and human diabetes mellitus were significantly changed

($p < 0.05$) in the hyperglycemic group, including the BCAAs isoleucine, leucine and valine, GlycA, acetate, fatty acids, cholesterol, triglycerides, lipoprotein particle concentrations and composition, phenylalanine and lactate (Supplementary Table 9).

Excellent fit in logistic regression modeling (smallest AICs and AUC values > 0.9), indicating good predictive value for hyperglycemia, was observed for BCAAs and their ratios. Twenty metabolites had good fit (AUC < 0.8). 31 biomarkers had a high proportion of missing values, reducing the comparability with other metabolites due to different sample populations. There were 14 metabolites with good fit among these metabolites. Many of these metabolites are lipids, that have very low concentrations in healthy dogs, causing a high proportion of automatically rejected very low values by platform quality control.

Discussion

Metabolomics is a rapidly growing field holding great potential for numerous clinical and scientific applications. Amongst various approaches, NMR spectroscopy is currently the most promising metabolomics method for clinical use due to its' quantitative nature, high-throughput, accuracy and speed, all of which are currently not achievable with MS based metabolomics. In this study, we describe a novel, cost-effective NMR metabolomics testing platform for dogs. A similar approach has previously been demonstrated and widely utilized in human metabolomics⁴⁰. The testing platform is capable of quantifying 123 biomarkers from a 100 μ l sample of serum, heparin plasma, EDTA plasma or citrate plasma. The throughput for one device is ~200 samples per 24 hours and around 70,000 samples per year. The turnaround time is currently 5 days and can be markedly reduced. These characteristics make this comprehensive metabolomics platform a new high-throughput method to facilitate veterinary research and clinical diagnostics with significant implications on treatment, care and well-being of dogs.

Recent advances in metabolomics research are paving the way from diagnostics based on single biomarkers to a more holistic approach. Especially the management of chronic metabolic diseases is thought to benefit from a methodology capable of generating comprehensive information on the metabolic state of the individual, enabling a personalized approach to management of the disease³⁴. Metabolomics is also proving itself valuable in disease risk prediction^{33,42-44}.

In contrast to genetics, metabolomics offers real-time information of the metabolic state of the animal, taking environmental factors and treatment into account. This offers metabolomics the possibility to be utilized as both a diagnostic tool as well as a follow-up tool. The advantage of the holistic nature of the NMR metabolomics platform was demonstrated in the comparison of hyperglycemic samples to normoglycemic samples from a routine laboratory

diagnostic sample population. The NMR metabolomics platform was able to identify a plethora of biomarkers with significant differences between the hyperglycemic group and the normoglycemic group, including BCAAs, GlycA, acetate, fatty acids, cholesterol, triglycerides and lipoprotein particle concentrations and composition, phenylalanine and lactate. Many of these changes have been associated with canine and human diabetes mellitus, and even diabetes risk before disease onset^{16,25,34,42,44}. This suggests the possibility of the NMR metabolomics platform to enhance preventative and precision veterinary medicine by providing new therapeutic targets and prognostic diagnostic markers.

In addition to a set of well-known clinical chemistry analytes, the established metabolomics platform includes a wide range of previously clinically unquantified biomarkers. One of the most interesting novel biomarkers is GlycA, a composite systemic inflammatory biomarker comprised of signals of acute-phase proteins α 1-acid glycoprotein, haptoglobin, α 1-antitrypsin, α 1-antichymotrypsin, and transferrin, with a slight contribution of glycosylated apolipoproteins⁴⁵. In humans, GlycA has been linked with systemic inflammation, cardiovascular disease risk, diabetes mellitus, pregnancy, severe infection and all-cause mortality^{28,45-49}. GlycA was also changed in our hyperglycemic group.

Formation of reference intervals is an important prerequisite for the clinical use of new laboratory method. We established reference intervals for 123 analytes, most of which are previously unpublished. The reference intervals differed between puppies, adult and senior dogs for many of the analytes, confirming substantial metabolic changes occurring during the maturation of the individual⁵⁰⁻⁵³. The higher reference limit of GlycA in senior than adult dogs suggests a higher prevalence of subclinical disease in older animals. The sample tube validation study demonstrated, that reference intervals created for the same sample type should be used in interpretation of the results. It should also be noted, that glycine and pyruvate cannot be quantified from EDTA plasma, and glutamine is not quantifiable from oligofin oligomer gel tubes.

Clinical use of a new laboratory method requires excellent method precision. The precision study suggested, that the precision of the NMR metabolomics platform is generally outstanding. For histidine, acetate, phenylalanine/tyrosine and BCAA/tyrosine, further studies in diseased animals are needed to conclude, whether measurement imprecision affects clinical utilization of these analytes.

The analytical method should be considered when evaluating laboratory results against treatment guidelines and reference intervals³⁹. The method comparison study revealed a linear relationship between the conventional and NMR method for all analytes, but all results cannot be evaluated interchangeably. Triglyceride measurements showed most variability between the two methods, explained by differences in methodology, sample handling and biological

characteristics. Analysis with the conventional method was done immediately, whereas NMR aliquots were frozen and one batch partly thawed during shipment. The methodology is also different, NMR measures triglycerides within lipoprotein particles, whereas the conventional method is based on interaction with the triglyceride molecule. Lipemia also affects the precision of triglyceride analyses, which causes more variability in high analyte concentrations. Correct preanalytical measures are considered essential for the integrity of laboratory results^{54,55}. An appropriate sample drawing technique is crucial for avoiding hemolysis, fasting before sample drawing for avoiding lipemia and prompt RBC separation for avoidance of prolonged RBC metabolism. Hemolysis, bilirubinemia, lipemia and prolonged contact with RBC all affected the quantification of certain metabolites. The profound impact of chylomicronemia on method precision was caused by matrix heterogeneity due to the chylomicron cream layer formation, which could be reduced by sample mixing immediately before analysis. Glycolysis-related metabolites are especially sensitive to contact with RBC, causing plasma samples to have different concentrations of these analytes than serum samples. Prolonged contact to RBCs affected also amino acids, which might explain why amino acid stability was better in our storage study using plasma and serum samples, than in previous studies using whole blood^{56,57}.

It is critical to use sample storage and shipping conditions that preserve the integrity of laboratory results. All tested analytes were stable at refrigerator temperature for one week, making refrigerated temperature the optimal sample short-term storage and shipping temperature. Sample storage at room temperature should be minimized. Most amino were more stable in EDTA-plasma samples than in serum samples in room temperature, which has also been reported in previous studies⁵⁷. The gold standard for long-term storage of serum/plasma metabolomics samples is freezing the samples immediately after serum/plasma separation and keeping them frozen at -80°C until analysis and avoiding additional freeze-thaw cycles⁵⁸. All of the tested analytes remained stable during one year of storage at -80°C. Two weeks of storage in -20°C was suitable for most of the analytes.

Limitations of this study include, that the precision and interference studies did not include samples at clinical decision levels for all metabolites. Since the NMR platform is so extensive, acquiring these samples would have been extremely difficult. The sample numbers especially in heparin plasma, were a limitation of the storage study. Limitations of the method comparison study include lack of a reference method generating results that could be viewed as true values of the analyte. No clinical data was available for the hyperglycemia study, thus the study should be repeated with samples in confirmed diabetic animals. The identified analytes should also be studied for multicollinearity.

Owing to the advantages of quantitative results, high throughput and reproducibility, the NMR-based metabolomic platform developed and validated here holds great potential for numerous clinical and research applications in

veterinary medicine. The performance of the NMR testing platform is generally outstanding and typical blood drawing and processing guidelines ensure the integrity of the results. The diagnostic power of the established metabolomics panel comes from the wide representation of markers from various molecular groups, including amino acids, fatty acids, glycolysis-related metabolites and lipoproteins. This enables efficient monitoring of physiologic changes in health and disease by the identification of condition-specific metabolic fingerprints.

Materials and Methods

Proton NMR spectroscopy

Metabolic profiling was conducted using a proton nuclear magnetic resonance (NMR) metabolomics technique similar to what has been demonstrated for human samples in Soininen et al.⁴⁰. The fully automated process is capable of quantifying 200 samples per 24 hours and the throughput for one device is around 70,000 samples per year. Usable sample types are serum, EDTA-plasma, heparin plasma and citrate plasma. Since the concentration of the tested molecule is in a linear relationship with NMR signal intensity, the linearity of NMR results is considered inherently outstanding.

The NMR testing method was calibrated by firstly collecting 1008 canine EDTA-plasma samples and 120 serum samples from client-owned dogs and running the samples with NMR. Only samples with plasma/serum separation done within one day of sample collection were used for initial method calibration, resulting in 847 EDTA-plasma samples and all 120 serum samples. The characteristic NMR signals of amino acids, glycolysis related metabolites, creatinine, and GlycA are well-known, and the quantitative and linear relationship between the signal intensity and molecular concentration is an inherent property of NMR. Thus, these biomarkers can be quantified using the established NMR techniques. The identification of signals for triglycerides, cholesterol, and lipoprotein subclass particles and lipids was verified by analyzing 200 of the previously collected EDTA-plasma samples with different lipid concentrations by high-performance liquid chromatography⁵⁹. For these measures, the concentration range of the automated NMR spectral analysis was also calibrated against these results.

Once the initial method calibration was completed, we collected a total of 4683 serum and 495 lithium heparin plasma samples across Finland during fall 2017-fall 2018 for use in our canine NMR metabolomics project. Samples were collected from dogs of all available breeds, with an emphasis of including dogs from genetically and morphologically different breed groups. Samples were drawn by cephalic venipuncture from client-owned dogs. Serum samples were collected into MiniCollect serum gel tubes and were allowed to clot for 30-45 minutes before centrifuging them at 3,000

x g for 10 minutes to separate the serum. Heparin plasma samples were collected into MiniCollect lithium heparin plasma gel tubes and the samples were immediately centrifuged at 3,000 x g for 10 minutes to separate plasma. All samples were then stored at -80°C before NMR analysis. All dog owners completed a history form, that included signalment and details about the health status, diet, exercise, stress and reproductive state of the dog.

The fatty acid panel verification and calibration was done using 100 samples with different lipid concentrations, collected for the canine NMR metabolomics project. Reference fatty acid concentrations were obtained using a chromatographical method by a commercial laboratory (Vitas as, Norway).

Reference intervals

Determination of reference intervals (RI) of healthy dogs was performed according to the American College of Veterinary Clinical Pathology (ASVCP) reference interval guidelines³⁹. We used the population-based nonparametric method for RI calculation, and calculated 90% confidence intervals (CI) for the reference limits. A minimum of 120 samples is required for the use of this method. Inclusion in RI calculation was based on fasting duration (minimum of 12 hours), appropriate sample handling, and the lack of owner-reported biological confounding factors, including diseases, severe anxiety/stress and strenuous exercise before blood collection.

A total of 865 samples collected for the canine NMR metabolomics project were included in the serum RI calculations. The samples were chosen to include over 120 samples of puppies (under 1 year old), adults (1-7 years old) and senior dogs (over 7 years old), to be able to calculate age-specific reference ranges. The 865 samples consisted of individuals from 68 breeds, 347 males and 517 females, 152 puppies, 545 adult dogs and 168 senior dogs.

A total of 269 samples out of the initial 495 samples collected for the canine NMR metabolomics project were qualified for lithium heparin plasma RI calculations. They consisted of individuals from 83 breeds, 155 males and 114 females, 29 puppies, 196 adult dogs and 44 senior dogs. Age-specific RI could be calculated for adult dogs.

Each metabolite was examined for outliers before RI calculation. We used Box Cox transformation to find a normal transformation, and Horn's algorithm in the transformed data to identify the outliers. In Horn's algorithm, the criterion for rejection of values is exceeding interquartile (IQ) fences set at $Q1 - 1.5 \cdot IQR$ and $Q3 + 1.5 \cdot IQR$ ($IQR = \text{interquartile range}$; $IQR = IQ3 - IQ1$ where $IQ1$ and $IQ3$ are the 25th and 75th percentiles, respectively. Once we identified the outliers, the sample and animal data were thoroughly reviewed for confounding analytical and preanalytical factors before reaching a conclusion about sample exclusion. In metabolites, in which normal distribution was not found, Horn's algorithm offered multiple outliers, which all were reviewed before reaching a conclusion about exclusion.

After calculating the RIs and the 90% CIs for lower and upper reference limits, we studied the relation between 90% CIs and RI. It is recommended that CI should not exceed 0.2 times the width of the RI, since it may indicate, that the sample number is insufficient.

Differences between RI for different age groups were evaluated by comparing the 90% CI of reference limits of puppies and senior dogs to the 90% CI of reference limits of adult dogs. Differences in the reference limits were concluded to be present, when there was no overlap between the 90% CI of reference limits between the two groups.

Precision

Precision of the NMR method was tested using three biologically different dogs (puppy, healthy adult, senior dog suffering from hyperadrenocorticism). Blood was drawn by cephalic venipuncture into Vacuette 8ml Z Serum Sep Clot Activator tubes. Samples were allowed to clot for 30-45 minutes and centrifuged at 2,000 x g for 10 minutes to separate serum. Every sample was divided into 40 aliquots of 100µl. All samples were stored at -80°C before NMR analysis. Two duplicate aliquots of each sample were analyzed each day during a twenty-day time period.

The sample from the senior dog suffering from hyperadrenocorticism had marked chylomicronemia with a chylomicron coat forming on the top of the stored serum aliquots. The results of this sample were used to determine the effect of chylomicronemia on test precision.

Total within-laboratory precision estimates were expressed both as coefficient of variation (CV%) and standard deviation (S_T). These within-laboratory precision estimates were evaluated against laboratory precision goals. We also calculated within-run precision, expressed as within-run standard deviation (S_r). All precision estimates were calculated using methods described in CLSI EP5-A3⁶⁰. Outlier detection was based on comparison of the absolute difference of the two duplicate aliquots analyzed in the same run to the mean absolute difference of all duplicates from the same sample. A difference that exceeded the mean absolute difference fourfold was set as the rejection line. If an outlier was detected, the duplicate was excluded from the calculations.

The currently most advisable hierarchy for performance specifications for human diagnostic laboratories is: 1. biological outcomes, 2. biological variation and 3. state-of-the-art^{61,62}. Biological outcome-based performance goals cannot be used in veterinary medicine, since they have not yet been published for animals. Canine CV% goals based on biological variation are available for only a few analytes and can be so strict, that they are unachievable by clinical laboratories and do not affect interpretation of the results⁴¹. State-of-the-art goals can lack accuracy and might not fit all analytes. Due to the lack of specific performance goals for all analytes, we evaluated the precision results against a set of performance goals.

In this study, ASVCP goals based on biological variation were set as the primary goals for CV%, since they are the only canine-specific precision goals available⁴¹. The total accuracy of veterinary laboratory results is typically evaluated using Observed Total Error (TE_{obs}) and evaluating it against against preset Total Allowable Error (TE_a) limits. TE_{obs} can be calculated as TE_{obs} = Bias% + 2CV%. Bias was not applicable for this study as a deviation from a true value⁴¹. This led us to use ½ of ASVCP TE_a limits based on Clinical Decision Limits as our secondary precision goals for CV%. If ASVCP goals were not set, we used 20% as the goal for CV% (CV_{maxBG}), which is generally considered an acceptable laboratory error in metabolomics^{63,64}. Since individual CV% max goals were not available for most of the analytes and the 20% CV% goal might not be descriptive enough for metabolites that have a very wide or narrow reference range due to inter-individual biological variation, we additionally compared the S_T to the S_{Tmax} goal of 1/8 of the width of the reference range. This goal was based on the finding, that analytical variation over one quarter of the reference range is considered to affect the clinical interpretation of the results⁶⁵. The S_{Tmax} goals based on 1/8 of the reference range width were very descriptive of the effects of imprecision on clinical interpretation of the results, but have the drawback, that imprecision affects the width of the reference range, itself⁶⁶.

Sample storage study

To define the effects of sample storage and shipping conditions on analyte results, we studied the effects of both long- and short-term sample storage. Short-term storage was studied in room temperature and refrigerated temperature, and long-term storage at -20°C and -80°C. To define storage effects in different sample matrices, we used three different sample matrices: serum, EDTA-plasma and heparin plasma. The protocol of the sample storage study is presented in Table 4.

To study storage effects in these above-mentioned sample matrices, we took serum and EDTA plasma samples of seven client-owned dogs in a separate sampling situation, and heparin plasma samples of four dogs in another sampling situation.

During the sample collection of EDTA plasma and serum samples for the storage study, blood was drawn by cephalic venipuncture into Vacuette serum gel tubes and Vacuette EDTA K2 tubes. Samples were centrifuged and separated according to the tube manufacturers' recommendations. EDTA-plasma samples were immediately centrifuged and plasma separated. Serum samples were allowed to clot for 30-45 minutes before centrifuging to separate serum. Separated plasma and serum were divided into 24 aliquots and stored in conditions outlined in Table 1 before immediate analysis with proton NMR spectroscopy.

Heparin plasma samples for the storage study were collected by drawing blood by cephalic venipuncture into Vacuette Lithium Heparin tubes. Samples were immediately centrifuged and plasma separated. The samples were divided into 13 aliquots and stored in conditions outlined in Table 4. After storage of samples in these test conditions, all samples were kept at -80°C for 2-3 weeks before NMR analysis.

Table 4. Sample storage study protocol.

Storage time (T_x)	Storage temperature			
	Sample transport simulation		Sample storage simulation	
	Room temperature	Refrigerator	-20°C	-80°C
0 hours (T_0)	S, EDTA, HP			
8 hours	S, EDTA, HP	S, EDTA, HP		
24 hours	S, EDTA, HP	S, EDTA, HP		
48 hours	S, EDTA, HP	S, EDTA, HP		
72 hours	S, EDTA, HP	S, EDTA, HP		
96 hours	S, EDTA, HP	S, EDTA, HP		
1 week	S, EDTA, HP	S, EDTA, HP	S, EDTA	S, EDTA
2 weeks			S, EDTA	S, EDTA
1 month			S, EDTA	S, EDTA
3 months			S, EDTA	S, EDTA
6 months			S, EDTA ^a	S, EDTA
12 months				S, EDTA ^a

S: serum

EDTA: EDTA plasma

HP: lithium heparin plasma

^a The EDTA plasma yield of two included dogs was slightly smaller than expected due to high hematocrit. For both dogs, one storage time point had to be excluded. The other sample was excluded from the 6 months storage of EDTA plasma at -20°C and the other one from 12 months storage of EDTA plasma in -80°C.

We used the two-sided Wilcoxon exact test to estimate the statistical significance of the changes in analyte values during sample storage. The test was performed between samples not subjected to storage (T_0) and samples subjected to different storage conditions at each storage time point (T_x) in each storage temperature (Table 4). Two-sided p-values of Wilcoxon test statistic less than 0.05 indicated a statistically significant difference between metabolite values in T_0 and T_x .

In addition to the Wilcoxon test, we calculated the mean percentage deviation (MPD)

$$MPD = \left(\frac{T_{x\text{mean}} - T_{0\text{mean}}}{T_{0\text{mean}}} \right) \times 100,$$

to indicate the stability/instability, as well as magnitude of change in metabolite values over a period of time⁶⁷. MPD was compared to the acceptable change limit (ACL), according to ISO 5725-6⁶⁸:

$$ACL = 2,77 CVa$$

The CVa was obtained from the precision study results presented in this study, calculated as the mean CV% of the non-chylomicronemic samples. The factor 2,77 was derived from $1.96 \times \sqrt{2}$, where 1.96 represents the 95% of confidence interval for bi-directional changes, and $\sqrt{2}$ was used as we compared two results with the same CVa. A MPD higher than the ACL represents a probable change in analyte concentration.

Outliers were detected by duplicate analysis of samples in storage time T_x and collection time T_0 . Cut points to set the sample as an outlier were

$$(\overline{T_x - T_0}) \pm 2 \cdot \text{STD}_{(T_x - T_0)},$$

where $\overline{T_x - T_0}$ is the mean and $\text{STD}_{(T_x - T_0)}$ the standard deviation between samples in storage time T_x and collection time T_0 .

If the difference $T_{xi} - T_{0i}$ of the sample i exceeded or undercut these cut points, it was defined as an outlier. All analyses were done as outliers included or not excluded in purpose to study the effect of outlier exclusion.

The criteria for clinically significant change was set so, that the change should be both statistically significant (p-value of the two-sided Wilcoxon exact test <0.05) and the magnitude of the change, evaluated as MPD, was required to be above the ACL, and the change was required to be consistent at the remaining time points. Sample stability was studied only in primary analytes, analyte stability was not evaluated in ratio and percentage analytes.

Delayed plasma separation study

In the delayed plasma separation study, we defined, how delays of plasma separation time from the sample tube manufacturer's recommendations affect metabolite values. Delayed plasma separation was studied by storing samples as whole blood in refrigerated temperature for 24 and 48 hours before plasma separation.

Blood was drawn by cephalic venipuncture from 34 client-owned dogs into three Vacuette K2 EDTA tubes per dog. One of the tubes was centrifuged and plasma separated according to sample tube manufacturer's recommendations within one hour after blood sampling. The remaining two tubes were stored as whole blood in a refrigerator until centrifugation and plasma separation after 24 and 48 hours of storage. After plasma separation, all samples were stored at -80°C before NMR analysis. This experiment was conducted using an older version of the NMR testing platform, thus the number of tested analytes was smaller, and fatty acids were not quantified.

For statistical analyses, we used similar methods as in the sample storage study. We used the two-sided Wilcoxon exact test to assess the effect of storage time on the sample, and mean percentage deviation (MPD) to indicate stability/instability and magnitude of change. Acceptable change limits (ACL) were the same as in the storage study. Outlier detection followed the same procedure as in the storage study, and criteria for clinically significant change were set similarly as $p < 0.05$ and $MPD > ACL$. T_0 in the delayed plasma study represents plasma separated according to sample tube manufacturer's recommendations and T_x plasma separated after 24 and 48 hours.

Sample tube validation

To study, whether metabolite values differ between samples collected in different blood collection tubes (BCT), we studied both differences between different blood collection tubes and lot-to-lot variability within these tubes. The protocol was modified from the proposed blood collection tube validation process by Bowen and Adcock⁶⁹.

Thirty milliliters of blood was drawn from a cephalic iv-cannula from 20 dogs into seven different types of blood collection tubes; MiniCollect Serum Separator Clot Activator tube, Vacuette Z Serum Separator Clot Activator tube, Vacuette Z Serum Clot Activator tube, Vacuette K2 EDTA tube, MiniCollect Lithium Heparin Separator tube, Vacuette Lithium Heparin tube and Vacuette Lithium Heparin Separator tube. Each tube type was tested with two tubes from different lots. EDTA and lithium heparin samples were immediately centrifuged to separate plasma. Serum samples were allowed to clot for 30-45 minutes before serum separation. The centrifugation conditions for samples collected into MiniCollect tubes were 3,000 x g for 10 minutes, and 2,000 x g for 13 minutes for all other sample tube types. The tested sample tubes and their specifications are presented in Table 5. All samples were stored at -80°C before analysis with NMR spectroscopy. The sample tube validation was only conducted regarding primary analytes, not for ratio and percentage analytes.

Table 5. Specifications of the tested blood collection tubes in the sample tube validation study.

Blood Collection tube	Sample type	Clotting activator/anticoagulant	Gel type	Lots
MiniCollect Serum Gel Tube 0,8ml	Serum	Clotting activator SiO ₂	Acrylic gel	A: 171010 B: A18023K3
Vacurette Z Serum Separator Clot Activator 3,5ml	Serum	Clotting activator SiO ₂	Olefin oligomer gel	A: A17103HT B: A18024EJ
Vacurette Z Serum Clot Activator tube 2ml	Serum	Clotting activator SiO ₂	-	A: A170837S B: A180644P
Vacurette K2 EDTA Tube 2ml	EDTA-plasma	Spray-dried K2 EDTA 1,2-2 mg (waterless)/ 1 ml blood	-	A: A17063FX B: A18043H3
MiniCollect Plasma Gel Tube 0,8ml	Lithium heparin plasma	Spray-dried lithium heparin 18 I.U./1 ml blood	Acrylic gel	A: A17114HE B: A18013N7
Vacurette Lithium Heparin Tube 2ml	Lithium heparin plasma	Spray-dried lithium heparin 18 I.U./1 ml blood	-	A: A17083HR B: A180247F
Vacurette Lithium Heparin Separator 3ml	Lithium heparin plasma	Spray-dried lithium heparin 18 I.U./1 ml blood	Olefin oligomer gel	A: A17123YY B: A18053D8

We used the two-sided Wilcoxon exact test and mean percentage deviation (MPD) (detailed in 2.4 Sample storage study) to evaluate statistical significance of differences between the tubes.

Differences between different sample tubes were tested using this protocol:

- Study, which tubes give comparable results with the primary reference tube

The Vacurette Lithium Heparin tube was set as the primary reference tube (T_0) and all other tubes (T_x) were compared against it.

Since we hypothesized, that most of the differences between sample tubes would originate from differences between serum and plasma, we secondly studied, which serum tubes give comparable results.

- Study, which serum tubes give comparable results with the serum reference tube.

The Vacurette Z Serum Clot Activator tube was set as the serum reference tube (T_0) and all other serum tubes (T_x) were compared against it.

The average of the analyte values in the two lots was used in these calculations.

517

518 Lot-to-lot variability was tested using this protocol:

519 1) Compare the two lots of each tube to another.

520 Tubes in lot A were set as a reference tubes (T_0) and tubes in lot B (T_x) were compared against them

521 2) If lot-to-lot variability was observed, compare results of each lot to reference tubes. This was done to determine,
522 whether samples from both lots give comparable results to the other tube types.

523 Lots A and B were compared separately to the Vacuette Lithium Heparin and Vacuette Z Serum Clot Activator tubes.

524

525 The same outlier detection protocol was used as in the sample storage study (2.4), except that we used coefficient 3 for
526 STD (instead of 2) in cut points: $(\overline{T_x - T_0}) \mp 3 \cdot \text{STD}_{(T_x - T_0)}$. We set broader cut off limits for outlier detection for the
527 sample tube validation than for the storage study, since the outlier test was more sensitive due to more observations in
528 the sample tube validation than in the storage study.

529 In addition to the tests above, we calculated bias as mean difference of T_x and T_0 with 95% confidence intervals, to
530 highlight the limits in which the differences of the samples in tubes (or lots) T_x and T_0 lie.

531 Although metabolite quantification is possible from citrate tubes, we did not include this tube type in this study, since
532 this tube type is not generally used in clinical applications in this field.

533 **Interference**

534 We tested our metabolites for interference of hemolysis, lipemia, and unconjugated and conjugated bilirubin. The
535 testing protocol was derived from CLSI-EP7-A2⁷⁰.

536 Hemolysis interference was studied using two client-owned dogs. 5 ml heparinized blood was collected by cephalic
537 venipuncture for preparation of the hemolysis stock solution. The samples were centrifuged and plasma separated and
538 discarded. The red blood cells were saved for the preparation of hemolysis stock solution. The hemolysis stock solution
539 was prepared by the osmotic shock procedure. The hemoglobin concentrations of the hemolysates were measured by
540 ADVIA 2120i hematology analyzer (Siemens)⁷¹. The base of the test and control samples were created by collecting
541 5ml heparinized blood by cephalic venipuncture from the same dogs that were used for the preparation of the
542 hemoglobin stock solutions. Test samples containing 500 mg/dl hemoglobin were produced by adding a measured
543 volume of the same dog's hemolysate to the same dog's plasma sample to produce the end concentration of 500mg/dl
544 hemoglobin. Test samples containing 250mg/dl hemoglobin were prepared by mixing an equal amount of the same

dog's hemoglobin 500mg/dl test and control samples. All samples were divided into three aliquots and run as triplicates in the NMR analysis.

Bilirubin interference was studied by creating two sample pools (Pool 1 and Pool 2) from samples collected for the canine NMR metabolomics project. The sample pools were created so, that as many metabolite levels as possible would differ between the two pools. The baseline bilirubin concentrations of both pools were measured (540 nm) by a modified version of the acid diazo coupling (Malloy-Evelyn) method (Bilirubin Total (NBD), Thermo Fisher Scientific Oy, Finland), using a Konelab 60i chemistry analyzer⁷². The two pools were both divided into four pools, creating the bases for test and control pools for unconjugated bilirubin, and test and control pools for conjugated bilirubin. The test pools for conjugated bilirubin were prepared by adding bilirubin stock solution (201102 EMD Millipore) to the conjugated bilirubin test pool samples. The control pools for conjugated bilirubin were prepared by adding the same volume of water to the conjugated bilirubin control pool samples. The test pools for unconjugated bilirubin were prepared by adding bilirubin stock solution (2011 EMD Millipore) to the unconjugated bilirubin test pools. The control pools for unconjugated bilirubin were prepared by adding the same volume of NaOH to the unconjugated bilirubin control pool samples. All pools were divided into three aliquots and run as triplicates in the NMR analysis.

Lipemia interference was studied by pooling lipemic serum samples collected for the canine NMR metabolomics project. The test pool was created so, that the triglyceride concentration would be around 2mmol/l. The pool was divided into a test and control pool. The lipids of the control pool were cleared by ultracentrifugation. Both samples were divided into three aliquots and run as triplicates by NMR.

We used CLSI-EP7-A2⁷⁰ guidelines as the base for our statistical testing. Interference testing was only evaluated regarding primary analytes, analyte stability was not evaluated in ratio and percentage analytes. Our testing was based on the point estimate of the observed interference effect (d_{obs}) and the cut-off value (d_c) and the comparison of these values.

The interference d_{obs} was defined as difference between the means of the test and control samples:

$d_{obs} = \bar{x}_{test} - \bar{x}_{control}$, where test and control samples indicate samples with and without the interfering subject, respectively.

The cut-off value d_c was defined as $d_c = \frac{d_{null} + sz_{1-\alpha/2}}{\sqrt{n}}$, where d_{null} represented the assumed difference between the means of test and control samples (set to 0), n was the number of replicates ($n=3$) and s was the mean within-laboratory

standard deviation (S_T) of non-lipemic samples obtained from the precision study results presented in this study. 95% confidence intervals for the d_{obs} were calculated as

$$d_{obs} = \bar{x}_{test} - \bar{x}_{control} \pm t_{0.975, n-1} S \sqrt{\frac{2}{n}}.$$

We established our decision of interference in the lower 95% limit of interference limit $d_{obs,low}$ - interference was concluded to be present, if $d_{obs,low} > d_c$ in at least one primary sample/sample pool, since properties of the sample matrix and/or analyte concentrations might affect the presence of interference. Hemolysis interference was concluded to be present if $d_{obs,low} > d_c$ in at least the higher hemolysate concentration of 500mg/dl hemoglobin. Lipemia interference was only evaluated for molecules other than lipids, since the lipid removal process inevitably decreases the concentration of these molecules.

Method comparison

The method comparison study was designed to evaluate, whether results from the routine clinical chemistry analytes included in the NMR metabolomics platform are comparable with results obtained by a conventional clinical chemistry method. The evaluated analytes were glucose, lactate, creatinine, albumin, cholesterol and triglycerides. In this study, bias was only evaluated as a measure of method interchangeability, since the values obtained by the conventional method cannot be regarded as true values of the analyte.

Clinical canine samples ($n = 999$) were studied by both NMR and standard clinical chemistry analysis methods. The samples included both heparin plasma and serum samples. The used samples were routine diagnostic sample material submitted by veterinarians across Finland, sent by mail to a single laboratory provider (Movet Ltd, Kuopio, Finland). Upon arrival, the samples were divided into two aliquots. One aliquot was immediately analyzed with conventional laboratory methods. Triglycerides were analyzed by a photometric method, cholesterol by a colorimetric method, albumin by a colorimetric method using bromocresol green, glucose by a photometric method using hexokinase, creatinine by a colorimetric enzymatic method and lactate by an enzymatic photometric method. The other aliquot was frozen and kept at -20°C for a maximum of 4 weeks before shipment to NMR analysis. The samples were sent in three batches on cool packs to NMR analysis, shipping time 7-14 hours. After arrival at the NMR laboratory, the samples were again stored at -80°C before NMR analysis. One of the sample shipments was sent over a 14h period on cool packs and partly thawed during shipment. Samples that were sent with a 7h shipment duration remained frozen during transportation. 404 of the samples were used for scaling the NMR albumin measurement, and thus excluded from the method comparison of albumin.

Statistical analysis followed the ASVCP General Quality Control Guidelines⁷³. Agreement of the results was viewed using a comparison plot with values the NMR method plotted on the y-axis and the conventional method on the x-axis. Agreement plots were created for raw data and logarithm transformed data. Bland-Altman plots⁷⁴ were used to visualize the distribution of differences.

We utilized Deming regression^{75,76} in calculation of slope and intercept for all analytes, and in addition, linear regression for analytes with correlation over 0,99. Agreement of Deming transformed data was visualized by adding an agreement plot for data in which conventional method data was transformed using Deming regression coefficients. To determine the mean bias in the unit of the analyte at both ends of the reference intervals, bias was determined by slope and intercept of the Deming regression for these points:

$$\text{Bias} = X_c(\text{slope} - 1) + \text{intercept},$$

where X_c is the corresponding end of the reference interval.

To determine the interchangeability of results obtained by the conventional and NMR method, TE_{obs} was evaluated against ASVCP clinical chemistry guidelines based on Clinical Decision Limits⁴¹, which reflect the maximum values that would affect clinical decision-making. Observed Total Error TE_{obs} was calculated using the formula⁴¹:

$$TE_{obs} = 2CVa + \text{Bias}\%,$$

where CVa was the mean CV% of the non-lipemic samples in the precision study and the mean bias percentage (Bias%) was calculated using the formula⁴¹:

$$\text{Bias}\% = \frac{\text{Mean}_{\text{NMR}} - \text{Mean}_{\text{conventional}}}{\text{Mean}_{\text{conventional}}} \times 100.$$

Hyperglycemia-associated biomarkers

In order to demonstrate the utility of the developed method in an important biological question, we studied the differences in metabolite profiles in a hyperglycemic and normoglycemic group. We used the results of the 999 clinical canine samples utilized in the method comparison study as our base population for the study. No clinical data was available for the samples.

Diabetes mellitus is defined as a disorder, where blood glucose continuously rises over the renal glucose reabsorption threshold of 11 mmol/l, causing glucosuria. The inclusion criteria to the case group (n = 24) was set as a NMR-measured glucose concentration over 11 mmol/l. Inclusion to the control group (n=781) was based on the NMR-measured glucose being within the serum all dogs' reference interval (4.4-6.8 mmol/l). Since the control group consisted of clinical samples submitted to a clinical laboratory, the control group most likely includes animals suffering from diseases, that do not cause hyperglycemia.

To define metabolic changes associated with hyperglycemia, we calculated the means and their 95% CI for the case and control groups as well as the effect sizes of the observed changes. To visualize the differences in analyte concentrations between the two groups, we plotted histograms of the analyte data of the two groups. The significance of the difference between the metabolite values in the case and control group was studied using the two-sided Wilcoxon test's Bonferroni-corrected p-values, with the cut-off for statistical significance set as $p < 0.05$.

To evaluate the metabolite's ability of predicting hyperglycemia, we used single-variable logistic regression, in which case-control status served as the response variable and individual metabolites as dependent variables. Together with the metabolite's maximum likelihood estimate's p-value (significant < 0.05), area under the curve (AUC) values calculated for the model were used to determine the predictability of hyperglycemia, when the abnormal metabolite value is present. The higher the AUC value is (≤ 1), the better the fit of the model in terms of predicting ability; 0.7 being the cut point for fair, 0.8 for good and 0.9 for excellent model. Akaike information criterion (AIC) was performed in comparison of the models using different metabolites. It has no cut-off point and a lower AIC indicates better model, assuming that the test population in the models is the same. Glucose was excluded from this analysis, since it was used to define the case and control groups.

All calculations and plotting conducted throughout this study were performed by SAS version 9.4, SAS Institute Inc., Cary, NC, USA and Microsoft Office Excel, Microsoft Corp., Redmond, WA, US.

Acknowledgements

We thank Kibble Labs Ltd. for the development and calibration of the canine NMR metabolomics platform, as well as NMR analysis of all samples. We thank Petra Jaakonsaari, Oona Mäki, Lea Mikkola, Marjo Hytönen and Maria Kaukonen for sample collection and Ileana Quintero for sample preparation for the interference experiment. Thomas Grönthal in the Veterinary Teaching Hospital, University of Helsinki, is acknowledged for performing the hemoglobin and bilirubin concentration measurements. We thank Sini Karjalainen, Kaisu Hiltunen, Reetta Hänninen, Juulia

Tuominen, Kaisa Kyöstiä, Riika Sarviaho, Milla Salonen, and multiple veterinary students for help with sample collection and handling, and César Araujo for help with sample metadata management. We thank Tuomas Poskiparta, Katja Jauni, Jonas Donner, Heidi Anderson, Päivi Ruotanen, Julia Bouirmane, Essi Pekkala, Igor Polyakov, Leena Honkanen for help in participant acquisition, planning of data management and help in project conceptualization. We thank MediSapiens Ltd. for sample data and metadata management. We thank our collaborators Faunatar and ShowHau Center for enabling sample collection in their premises. We thank Movet Ltd. for the acquisition of the method comparison samples, and their analysis with conventional clinical chemistry methods. The authors also want to thank all dog owners, who offered their pets to participate in the study.

Author Contributions

HL and CO conceptualized the study. CO, JP, LV, KV and HL designed the study. HL, CO, JP and LV participated in sample recruitment and collection. KV and CO conducted statistical analyses. HL supervised the study. CO drafted the manuscript with the help from other authors. All authors read and approved the final manuscript.

Funding

The study was funded by PetBiomics Ltd.

Author Conflict of Interest Statement

CO is an employee, KV a previous employee, and HL is an owner and the Chairman of the Board of PetBiomics Ltd.

Ethical Approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted. Committee: Finnish national Animal Experiment Board, permit number: ESAVI/7482/04.10.07/2015.

Data availability

The datasets generated during the current study are available from the corresponding authors upon request.

References

1. Colyer, A., Gilham, M. S., Kamlage, B., Rein, D. & Allaway, D. Identification of intra- and inter-individual metabolite variation in plasma metabolite profiles of cats and dogs. *Br. J. Nutr.* **106 Suppl**, S146-9 (2011).
2. Richards, S. E. *et al.* Self-modeling curve resolution recovery of temporal metabolite signal modulation in NMR spectroscopic data sets: application to a life-long caloric restriction study in dogs. *Anal. Chem.* **80**, 4876–

688 4885 (2008).

689 3. Hall, J. A., Brockman, J. A. & Jewell, D. E. Dietary fish oil alters the lysophospholipid metabolomic profile and
690 decreases urinary 11-dehydro thromboxane B(2) concentration in healthy Beagles. *Vet. Immunol.*
691 *Immunopathol.* **144**, 355–365 (2011).

692 4. Allaway, D. *et al.* Metabolomic profiling to identify effects of dietary calcium reveal the influence of the
693 individual and postprandial dynamics on the canine plasma metabolome. *J. Nutr. Sci.* **8**, e13 (2019).

694 5. Hall, J. A., Jackson, M. I., Vondran, J. C., Vanchina, M. A. & Jewell, D. E. Comparison of circulating
695 metabolite concentrations in dogs and cats when allowed to freely choose macronutrient intake. *Biol. Open* **7**,
696 (2018).

697 6. Allaway, D. Nutritional Metabolomics: Lessons from Companion Animals. *Curr. Metabolomics* **80** (2015).
698 doi:<https://doi.org/10.2174/2213235X03666141216203315>

699 7. Richards, S. E. *et al.* Metabolic phenotype modulation by caloric restriction in a lifelong dog study. *J. Proteome*
700 *Res.* **12**, 3117–3127 (2013).

701 8. Middleton, R. P. *et al.* Metabolic Differences between Dogs of Different Body Sizes. *J. Nutr. Metab.* **2017**,
702 4535710 (2017).

703 9. Lloyd, A. J. *et al.* Characterisation of the main drivers of intra- and inter- breed variability in the plasma
704 metabolome of dogs. *Metabolomics* **12**, 72 (2016).

705 10. Yan, G. *et al.* Investigation of toxicological effects of Shuanghuanglian injection in Beagle dogs by
706 metabonomic and traditional approaches. *Exp. Biol. Med. (Maywood)*. **235**, 1356–1364 (2010).

707 11. Osaki, T. *et al.* Metabolomic analyses of blood plasma after oral administration of D-glucosamine
708 hydrochloride to dogs. *Mar. Drugs* **10**, 1873–1882 (2012).

709 12. Puurunen, J. *et al.* Fearful dogs have increased plasma glutamine and γ -glutamyl glutamine. *Sci. Rep.* **8**, 15976
710 (2018).

711 13. Puurunen, J. *et al.* A non-targeted metabolite profiling pilot study suggests that tryptophan and lipid
712 metabolisms are linked with ADHD-like behaviours in dogs. *Behav. Brain Funct.* **12**, 27 (2016).

713 14. Gamble, L.-J. *et al.* Serum metabolomics of Alaskan sled dogs during endurance racing. *Comp. Exerc. Physiol.*

14, 1–12 (2018).

15. Soh, P. X. Y. *et al.* Genome-wide association studies of 74 plasma metabolites of German shepherd dogs reveal two metabolites associated with genes encoding their enzymes. *Metabolomics* **15**, 123 (2019).

16. O’Kell, A. L., Garrett, T. J., Wasserfall, C. & Atkinson, M. A. Untargeted metabolomic analysis in naturally occurring canine diabetes mellitus identifies similarities to human Type 1 Diabetes. *Sci. Rep.* **7**, 9467 (2017).

17. Minamoto, Y. *et al.* Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease. *Gut Microbes* **6**, 33–47 (2015).

18. Söder, J. *et al.* Plasma metabolomics reveals lower carnitine concentrations in overweight Labrador Retriever dogs. *Acta Vet. Scand.* **61**, 10 (2019).

19. Li, Q. *et al.* Veterinary Medicine and Multi-Omics Research for Future Nutrition Targets: Metabolomics and Transcriptomics of the Common Degenerative Mitral Valve Disease in Dogs. *OMICS* **19**, 461–470 (2015).

20. Gookin, J. L., Mathews, K. G., Cullen, J. & Seiler, G. Qualitative metabolomics profiling of serum and bile from dogs with gallbladder mucocele formation. *PLoS One* **13**, e0191076 (2018).

21. Guard, B. C. *et al.* Characterization of microbial dysbiosis and metabolomic changes in dogs with acute diarrhea. *PLoS One* **10**, e0127259 (2015).

22. Lawrence, Y. A. *et al.* Untargeted metabolomic profiling of serum from dogs with chronic hepatic disease. *J. Vet. Intern. Med.* (2019). doi:10.1111/jvim.15479

23. Whitfield, P. D. *et al.* Metabolomics as a diagnostic tool for hepatology: validation in a naturally occurring canine model. *Metabolomics* **1**, 215–225 (2005).

24. Forster, G. M. *et al.* A Comparative Study of Serum Biochemistry, Metabolome and Microbiome Parameters of Clinically Healthy, Normal Weight, Overweight, and Obese Companion Dogs. *Top. Companion Anim. Med.* **33**, 126–135 (2018).

25. O’Kell, A. L., Garrett, T. J., Wasserfall, C. & Atkinson, M. A. Untargeted metabolomic analysis in non-fasted diabetic dogs by UHPLC--HRMS. *Metabolomics* **15**, 15 (2019).

26. Mora-Ortiz, M., Nuñez Ramos, P., Oregioni, A. & Claus, S. P. NMR metabolomics identifies over 60 biomarkers associated with Type II Diabetes impairment in db/db mice. *Metabolomics* **15**, 89 (2019).

27. Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R. & Griffin, J. L. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. *Chem. Soc. Rev.* **40**, 387–426 (2011).
28. Fischer, K. *et al.* Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. *PLoS Med.* **11**, e1001606 (2014).
29. Wurtz, P. *et al.* Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. *Am. J. Epidemiol.* **186**, 1084–1096 (2017).
30. Kettunen, J. *et al.* Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. *Nat. Commun.* **7**, 11122 (2016).
31. Wurtz, P. *et al.* Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: a note on Mendelian randomization studies. *Journal of the American College of Cardiology* **62**, 1906–1908 (2013).
32. Nicholson, J. K. Global systems biology, personalized medicine and molecular epidemiology. *Molecular systems biology* **2**, 52 (2006).
33. Ye, L. & Mao, W. Metabonomic biomarkers for risk factors of chronic kidney disease. *Int. Urol. Nephrol.* **48**, 547–552 (2016).
34. Klein, M. S. & Shearer, J. Metabolomics and Type 2 Diabetes: Translating Basic Research into Clinical Application. *J. Diabetes Res.* **2016**, 3898502 (2016).
35. Kwo, P. Y., Cohen, S. M. & Lim, J. K. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. *Am. J. Gastroenterol.* **112**, 18–35 (2017).
36. Koulouri, O., Moran, C., Halsall, D., Chatterjee, K. & Gurnell, M. Pitfalls in the measurement and interpretation of thyroid function tests. *Best Pract. Res. Clin. Endocrinol. Metab.* **27**, 745–762 (2013).
37. Braun, J. P., Lefebvre, H. P. & Watson, A. D. J. Creatinine in the Dog: A Review. *Vet. Clin. Pathol.* **32**, 162–179 (2003).
38. Zatelli, A., D'Ippolito, P., Roura, X. & Zini, E. Short-term effects of dietary supplementation with amino acids in dogs with proteinuric chronic kidney disease. *Can. Vet. J. = La Rev. Vet. Can.* **58**, 1287–1293 (2017).

39. Friedrichs, K. R. *et al.* ASVCP reference interval guidelines: determination of de novo reference intervals in veterinary species and other related topics. *Vet. Clin. Pathol.* **41**, 441–453 (2012).
40. Soininen, P. *et al.* High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. *Analyst* **134**, 1781–1785 (2009).
41. Harr, K. E., Flatland, B., Nabity, M. & Freeman, K. P. ASVCP guidelines: allowable total error guidelines for biochemistry. *Vet. Clin. Pathol.* **42**, 424–436 (2013).
42. Guasch-Ferre, M. *et al.* Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis. *Diabetes Care* **39**, 833–846 (2016).
43. Deelen, J. *et al.* A metabolic profile of all-cause mortality risk identified in an observational study of 44,168 individuals. *Nat. Commun.* **10**, 3346 (2019).
44. Wang, T. J. *et al.* Metabolite profiles and the risk of developing diabetes. *Nat. Med.* **17**, 448–453 (2011).
45. Otvos, J. D. *et al.* GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation. *Clin. Chem.* **61**, 714–723 (2015).
46. Connelly, M. A., Otvos, J. D., Shalurova, I., Playford, M. P. & Mehta, N. N. GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk. *J. Transl. Med.* **15**, 219 (2017).
47. Ritchie, S. C. *et al.* The Biomarker GlycA Is Associated with Chronic Inflammation and Predicts Long-Term Risk of Severe Infection. *Cell Syst.* **1**, 293–301 (2015).
48. Fizelova, M. *et al.* Differential Associations of Inflammatory Markers With Insulin Sensitivity and Secretion: The Prospective METSIM Study. *J. Clin. Endocrinol. Metab.* **102**, 3600–3609 (2017).
49. Wang, Q. *et al.* Metabolic profiling of pregnancy: cross-sectional and longitudinal evidence. *BMC Med.* **14**, 205 (2016).
50. Lepage, N., McDonald, N., Dallaire, L. & Lambert, M. Age-specific distribution of plasma amino acid concentrations in a healthy pediatric population. *Clin. Chem.* **43**, 2397 LP-2402 (1997).
51. von Dehn, B. Pediatric clinical pathology. *Vet. Clin. North Am. Small Anim. Pract.* **44**, 205–219 (2014).
52. Willems, A. *et al.* Results of Screening of Apparently Healthy Senior and Geriatric Dogs. *J. Vet. Intern. Med.* **31**, 81–92 (2017).

- 792 53. Usui, S., Mizoguchi, Y., Yasuda, H., Arai, N. & Koketsu, Y. Dog age and breeds associated with high plasma
793 cholesterol and triglyceride concentrations. *J. Vet. Med. Sci.* **76**, 269–272 (2014).
- 794 54. Braun, J.-P., Bourges-Abella, N., Geffre, A., Concordet, D. & Trumel, C. The preanalytic phase in veterinary
795 clinical pathology. *Vet. Clin. Pathol.* **44**, 8–25 (2015).
- 796 55. Thoresen, S. I., Havre, G. N., Morberg, H. & Mowinckel, P. Effects of storage time on chemistry results from
797 canine whole blood, heparinized whole blood, serum and heparinized plasma. *Vet. Clin. Pathol.* **21**, 88–94
798 (1992).
- 799 56. Davis, J. S. *et al.* Ex-vivo changes in amino acid concentrations from blood stored at room temperature or on
800 ice: implications for arginine and taurine measurements. *BMC Clin. Pathol.* **9**, 10 (2009).
- 801 57. Breier, M. *et al.* Targeted metabolomics identifies reliable and stable metabolites in human serum and plasma
802 samples. *PLoS One* **9**, e89728 (2014).
- 803 58. Kirwan, J. A. *et al.* Preanalytical Processing and Biobanking Procedures of Biological Samples for
804 Metabolomics Research: A White Paper, Community Perspective (for ‘Precision Medicine and
805 Pharmacometabolomics Task Group’-The Metabolomics Society Initiative). *Clin. Chem.* **64**, 1158–1182 (2018).
- 806 59. Okazaki, M. *et al.* Identification of unique lipoprotein subclasses for visceral obesity by component analysis of
807 cholesterol profile in high-performance liquid chromatography. *Arterioscler. Thromb. Vasc. Biol.* **25**, 578–584
808 (2005).
- 809 60. Clinical & Laboratory Standards Institute [CLSI]. Evaluation of Precision of Quantitative Measurement
810 Procedures; Approved Guideline – Third Edition. (2014).
- 811 61. Ceriotti, F. *et al.* Criteria for assigning laboratory measurands to models for analytical performance
812 specifications defined in the 1st EFLM Strategic Conference. *Clin. Chem. Lab. Med.* **55**, 189–194 (2017).
- 813 62. Sandberg, S. *et al.* Defining analytical performance specifications: Consensus Statement from the 1st Strategic
814 Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. *Clin. Chem. Lab. Med.*
815 **53**, 833–835 (2015).
- 816 63. Townsend, M. K. *et al.* Reproducibility of metabolomic profiles among men and women in 2 large cohort
817 studies. *Clin. Chem.* **59**, 1657–1667 (2013).
- 818 64. Rosner, B. *Fundamentals of Biostatistics*. (Duxbury Press, 2005).

65. Tonks, D. Quality Control Systems in clinical chemistry laboratories. *Postgrad. Med.* A58–A70 (1963).
66. Oosterhuis, W. Analytical performance specifications in clinical chemistry: the holy grail? *J. Lab. Precis. Med.* **2**, 78 (2017).
67. International Organization for Standardization [ISO]. Reference materials — Selected terms and definitions, ISO GUIDE 30:2015. (2015).
68. International Organization for Standardization [ISO]. Accuracy (trueness and precision) of measurement methods and results. ISO 5725:1994. (1994).
69. Bowen, R. A. R. & Adcock, D. M. Blood collection tubes as medical devices: The potential to affect assays and proposed verification and validation processes for the clinical laboratory. *Clin. Biochem.* **49**, 1321–1330 (2016).
70. Clinical & Laboratory Standards Institute [CLSI]. Interference Testing in Clinical Chemistry, 2nd Edition. (2005).
71. Bauer, N. & Moritz, A. Evaluation of three methods for measurement of hemoglobin and calculated hemoglobin variables with the ADVIA 120 and ADVIA 2120 systems in goats. *J. Vet. Diagn. Invest.* **20**, 593–597 (2008).
72. Parviainen, M. T. A modification of the acid diazo coupling method (Malloy-Evelyn) for the determination of serum total bilirubin. *Scand. J. Clin. Lab. Invest.* **57**, 275–279 (1997).
73. American Society for Veterinary Clinical Pathology [ASVCP]. Principles of quality assurance and standards for veterinary clinical pathology. (2009).
74. Bland, J. M. & Altman, D. G. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet (London, England)* **1**, 307–310 (1986).
75. Jensen, A. L. & Kjelgaard-Hansen, M. Method comparison in the clinical laboratory. *Vet. Clin. Pathol.* **35**, 276–286 (2006).
76. Linnet, K. Evaluation of regression procedures for methods comparison studies. *Clin. Chem.* **39**, 424–432 (1993).